Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
Domain	PKK	SLK STK10	5.42e-05	2	138	2	IPR022165
Domain	PKK	SLK STK10	5.42e-05	2	138	2	PF12474
Domain	NPIP	NPIPB3 NPIPB5 NPIPB13	1.35e-04	14	138	3	IPR009443
Domain	HDAC4_Gln	HDAC5 HDAC4	1.62e-04	3	138	2	PF12203
Domain	Hist_deacetylase_Gln_rich_N	HDAC5 HDAC4	1.62e-04	3	138	2	IPR024643
Domain	TRPM_tetra	TRPM3 TRPM1	3.22e-04	4	138	2	PF16519
Domain	Coact_PPARg	FAM120B FAM120A	3.22e-04	4	138	2	IPR026784
Domain	TRPM_tetra	TRPM3 TRPM1	3.22e-04	4	138	2	IPR032415
Domain	Histone_deAcase_II_euk	HDAC5 HDAC4	3.22e-04	4	138	2	IPR017320
Domain	DOCK_N	DOCK3 DOCK4	5.34e-04	5	138	2	PF16172
Domain	DOCK_N	DOCK3 DOCK4	5.34e-04	5	138	2	IPR032376
Domain	DUF4704	WDFY3 LRBA	5.34e-04	5	138	2	IPR031570
Domain	DUF4704	WDFY3 LRBA	5.34e-04	5	138	2	PF15787
Domain	PH_BEACH	WDFY3 LRBA	7.97e-04	6	138	2	PF14844
Domain	DHC_N1	DNAH8 DYNC1H1	1.47e-03	8	138	2	PF08385
Domain	PH-BEACH_dom	WDFY3 LRBA	1.47e-03	8	138	2	IPR023362
Domain	-	WDFY3 LRBA	1.47e-03	8	138	2	2.30.29.40
Domain	PH_BEACH	WDFY3 LRBA	1.47e-03	8	138	2	PS51783
Domain	Dynein_heavy_dom-1	DNAH8 DYNC1H1	1.47e-03	8	138	2	IPR013594
Domain	BEACH	WDFY3 LRBA	1.89e-03	9	138	2	PS50197
Domain	Beach	WDFY3 LRBA	1.89e-03	9	138	2	PF02138
Domain	-	WDFY3 LRBA	1.89e-03	9	138	2	1.10.1540.10
Domain	Beach	WDFY3 LRBA	1.89e-03	9	138	2	SM01026
Domain	BEACH_dom	WDFY3 LRBA	1.89e-03	9	138	2	IPR000409
Domain	VDCCAlpha1	CACNA1B CACNA1G	2.35e-03	10	138	2	IPR002077
Domain	Hist_deacetyl	HDAC5 HDAC4	2.85e-03	11	138	2	PF00850
Domain	DHR-1_domain	DOCK3 DOCK4	2.85e-03	11	138	2	IPR027007
Domain	DHR_2	DOCK3 DOCK4	2.85e-03	11	138	2	PS51651
Domain	DHR_1	DOCK3 DOCK4	2.85e-03	11	138	2	PS51650
Domain	DHR-2	DOCK3 DOCK4	2.85e-03	11	138	2	PF06920
Domain	-	HDAC5 HDAC4	2.85e-03	11	138	2	3.40.800.20
Domain	DOCK	DOCK3 DOCK4	2.85e-03	11	138	2	IPR026791
Domain	His_deacetylse_dom	HDAC5 HDAC4	2.85e-03	11	138	2	IPR023801
Domain	DOCK_C	DOCK3 DOCK4	2.85e-03	11	138	2	IPR010703
Domain	DOCK-C2	DOCK3 DOCK4	2.85e-03	11	138	2	PF14429
Domain	DHR-2	DOCK3 DOCK4	2.85e-03	11	138	2	IPR027357
Domain	His_deacetylse	HDAC5 HDAC4	2.85e-03	11	138	2	IPR000286
Domain	H15	H1-8 SHPRH	4.01e-03	13	138	2	SM00526
Domain	6-hairpin_glycosidase-like	MOGS AGL	4.01e-03	13	138	2	IPR008928
Domain	Linker_histone	H1-8 SHPRH	4.01e-03	13	138	2	PF00538
Domain	H15	H1-8 SHPRH	4.01e-03	13	138	2	PS51504
Domain	Histone_H1/H5_H15	H1-8 SHPRH	4.65e-03	14	138	2	IPR005818
Domain	Dynein_heavy_chain_D4_dom	DNAH8 DYNC1H1	4.65e-03	14	138	2	IPR024317
Domain	Dynein_HC_stalk	DNAH8 DYNC1H1	4.65e-03	14	138	2	IPR024743
Domain	Dynein_heavy_dom-2	DNAH8 DYNC1H1	4.65e-03	14	138	2	IPR013602
Domain	DHC_N2	DNAH8 DYNC1H1	4.65e-03	14	138	2	PF08393
Domain	ATPase_dyneun-rel_AAA	DNAH8 DYNC1H1	4.65e-03	14	138	2	IPR011704
Domain	IBR	RNF19B RNF216	4.65e-03	14	138	2	SM00647
Domain	PIN_domain-like	FAM120B FAM120A	4.65e-03	14	138	2	IPR029060
Domain	MT	DNAH8 DYNC1H1	4.65e-03	14	138	2	PF12777
Domain	AAA_8	DNAH8 DYNC1H1	4.65e-03	14	138	2	PF12780
Domain	Ferritin-like_SF	RRM2 SETD2	4.65e-03	14	138	2	IPR009078
Domain	AAA_5	DNAH8 DYNC1H1	4.65e-03	14	138	2	PF07728
Domain	DHC_fam	DNAH8 DYNC1H1	5.34e-03	15	138	2	IPR026983
Domain	Dynein_heavy	DNAH8 DYNC1H1	5.34e-03	15	138	2	PF03028
Domain	IBR_dom	RNF19B RNF216	5.34e-03	15	138	2	IPR002867
Domain	Dynein_heavy_dom	DNAH8 DYNC1H1	5.34e-03	15	138	2	IPR004273
Domain	ZF_RING_1	RNF19B TRIM43 FANCL ZNRF4 TRIM43B SHPRH RNF216	5.94e-03	291	138	7	PS00518
Domain	VWF_A	ITGAD ITIH2 ANTXRL MED25	6.25e-03	99	138	4	IPR002035
Domain	ZF_RING_2	RNF19B TRIM43 FANCL ZNRF4 TRIM43B SHPRH RNF216	6.74e-03	298	138	7	PS50089
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	DOCK3 PDE2A HIVEP2 TRIO INTS1 PER1 IDUA ZZEF1 ARSG TYK2 STK10 NCOR1 CELSR1 TNRC18 PSME4 ARVCF KLHL21 NEK8 NADK SLC7A5 AKAP13 WDFY3 LRBA SLC52A2 MBD5 DYNC1H1 FOXK1	9.71e-14	1105	144	27	35748872
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: IV. The complete nucleotide sequences of 500 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	DOCK3 KIF13B MYO6 GNPTAB PER1 SEMA4G PRX ARSG EFTUD2 SETD2 TNRC18 FAM120A TRPM3 MBD5 CSTF2T	2.43e-09	493	144	15	15368895
Pubmed	Pro-prion, as a membrane adaptor protein for E3 ligase c-Cbl, facilitates the ubiquitination of IGF-1R, promoting melanoma metastasis.	DOCK4 TRIO CNOT10 NPIPB11 RNF19B INTS1 ZNF318 STK10 NCOR1 MELTF TNRC18 TRPM3 AKAP13 MBD5 FOXK1	1.97e-07	689	144	15	36543142
Pubmed	Class II HDACs mediate CaMK-dependent signaling to NRSF in ventricular myocytes.	HDAC5 HDAC4 REST	2.77e-07	4	144	3	17011572
Pubmed	The histone deacetylase-3 complex contains nuclear receptor corepressors.	HDAC5 HDAC4 NCOR1	6.91e-07	5	144	3	10860984
Pubmed	Nuclear receptor corepressors partner with class II histone deacetylases in a Sin3-independent repression pathway.	HDAC5 HDAC4 NCOR1	1.38e-06	6	144	3	10640275
Pubmed	Breast cancer associated transcriptional repressor PLU-1/JARID1B interacts directly with histone deacetylases.	HDAC5 HDAC4 NCOR1	2.40e-06	7	144	3	17373667
Pubmed	Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR.	HDAC5 HDAC4 NCOR1	2.40e-06	7	144	3	11804585
Pubmed	Identifications of novel host cell factors that interact with the receptor-binding domain of the SARS-CoV-2 spike protein.	USP13 SLK OBSL1 ZZEF1 TYK2 FAM120A PSME4 MOGS ARVCF RNF216 AKAP13 YY1AP1 SLC33A1	3.39e-06	650	144	13	38777146
Pubmed	Large-scale characterization of HeLa cell nuclear phosphoproteins.	SF3A1 ZNF318 REST MED1 VIRMA ATF2 EFTUD2 TUBGCP6 STK10 NCOR1 SETD2 SLC7A5 YY1AP1 CSTF2T	4.46e-06	774	144	14	15302935
Pubmed	Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo.	HDAC5 HDAC4 NCOR1	5.73e-06	9	144	3	11466315
Pubmed	Chr21 protein-protein interactions: enrichment in proteins involved in intellectual disability, autism, and late-onset Alzheimer's disease.	SOX6 DOCK3 ATP6V1B2 USP13 PDE2A HIVEP2 TRIO MYO6 GNPTAB OBSL1 LRP1B PTPN13 FAM120A RNF216 YY1AP1 WDFY3 LRBA DYNC1H1	6.56e-06	1285	144	18	35914814
Pubmed	BCoR, a novel corepressor involved in BCL-6 repression.	HDAC5 HDAC4 NCOR1	8.17e-06	10	144	3	10898795
Pubmed	Recruitment of IkappaBalpha to the hes1 promoter is associated with transcriptional repression.	HDAC5 HDAC4 NCOR1	8.17e-06	10	144	3	15536134
Pubmed	An organelle-specific protein landscape identifies novel diseases and molecular mechanisms.	KIF13B HDAC5 HDAC4 CNOT10 SF3A1 ATG2B OBSL1 FANCL MED1 EFTUD2 PTPN13 OXA1L NEK8 NADK DYNC1H1 FOXK1 CCDC93 CCDC40	9.54e-06	1321	144	18	27173435
Pubmed	Proteome-scale mapping of binding sites in the unstructured regions of the human proteome.	DOCK3 HDAC5 AFF2 HDAC4 PRX STK10 NCOR1 TNRC18 AKAP13 DYNC1H1	1.32e-05	430	144	10	35044719
Pubmed	PRISMA and BioID disclose a motifs-based interactome of the intrinsically disordered transcription factor C/EBPα.	HDAC4 SF3A1 ETV6 ZNF318 MED1 RFC5 ATF2 GMPS STK10 NCOR1 TNRC18 FAM120A SMARCD1 DYNC1H1 FOXK1 CSTF2T	1.45e-05	1103	144	16	34189442
Pubmed	Molecular mechanisms regulating cell type specific expression of BMP/RA Inducible Neural-specific Protein-1 that suppresses cell cycle progression: roles of NRSF/REST and DNA methylation.	BRINP1 REST	1.70e-05	2	144	2	15193422
Pubmed	Negative correlation between Per1 and Sox6 expression during chondrogenic differentiation in pre-chondrocytic ATDC5 cells.	SOX6 PER1	1.70e-05	2	144	2	23883486
Pubmed	Disruption of the Class IIa HDAC Corepressor Complex Increases Energy Expenditure and Lipid Oxidation.	HDAC5 HDAC4	1.70e-05	2	144	2	27626651
Pubmed	Reaching and grasping phenotypes in the mouse (Mus musculus): a characterization of inbred strains and mutant lines.	KY DYNC1H1	1.70e-05	2	144	2	17574766
Pubmed	Nuclear calcium signaling regulates nuclear export of a subset of class IIa histone deacetylases following synaptic activity.	HDAC5 HDAC4	1.70e-05	2	144	2	23364788
Pubmed	Class IIa histone deacetylases link cAMP signaling to the myelin transcriptional program of Schwann cells.	HDAC5 HDAC4	1.70e-05	2	144	2	29472387
Pubmed	Transient receptor potential melastatin 1 (TRPM1) is an ion-conducting plasma membrane channel inhibited by zinc ions.	TRPM3 TRPM1	1.70e-05	2	144	2	21278253
Pubmed	Mutagenic insertion and chromosome engineering resource (MICER).	LRP1B PGAP1	1.70e-05	2	144	2	15235602
Pubmed	Nitric oxide modulates chromatin folding in human endothelial cells via protein phosphatase 2A activation and class II histone deacetylases nuclear shuttling.	HDAC5 HDAC4	1.70e-05	2	144	2	17975112
Pubmed	Class IIa HDACs regulate learning and memory through dynamic experience-dependent repression of transcription.	HDAC5 HDAC4	1.70e-05	2	144	2	31375688
Pubmed	Class II histone deacetylases downregulate GLUT4 transcription in response to increased cAMP signaling in cultured adipocytes and fasting mice.	HDAC5 HDAC4	1.70e-05	2	144	2	22403301
Pubmed	Recruitment of the nuclear receptor corepressor N-CoR by the TEL moiety of the childhood leukemia-associated TEL-AML1 oncoprotein.	ETV6 NCOR1	1.70e-05	2	144	2	11001911
Pubmed	Control of cardiac growth by histone acetylation/deacetylation.	HDAC5 HDAC4	1.70e-05	2	144	2	16397154
Pubmed	The histone deacetylase 9 gene encodes multiple protein isoforms.	HDAC4 ETV6 NCOR1	2.45e-05	14	144	3	12590135
Pubmed	Defining the membrane proteome of NK cells.	MYO6 CNOT10 INTS1 MED1 EFTUD2 TUBGCP6 NCOR1 BCL2L12 FAM120A MOGS SLC7A5 AKAP13 ATP13A3 LRBA SLC33A1 DYNC1H1	2.90e-05	1168	144	16	19946888
Pubmed	Spatiotemporal profile of postsynaptic interactomes integrates components of complex brain disorders.	KIF13B PDE2A SLK HDAC4 TRIO ZNF318 VIRMA SHISA7 EFTUD2 NCOR1 FAM120A ARVCF WDFY3 DYNC1H1	4.99e-05	963	144	14	28671696
Pubmed	Cooperative cobinding of synthetic and natural ligands to the nuclear receptor PPARγ.	MED1 NCOR1	5.09e-05	3	144	2	30575522
Pubmed	Histone deacetylases and the nuclear receptor corepressor regulate lytic-latent switch gene 50 in murine gammaherpesvirus 68-infected macrophages.	HDAC4 NCOR1	5.09e-05	3	144	2	20719946
Pubmed	Identification of a signal-responsive nuclear export sequence in class II histone deacetylases.	HDAC5 HDAC4	5.09e-05	3	144	2	11509672
Pubmed	Two olfactory receptors-OR2A4/7 and OR51B5-differentially affect epidermal proliferation and differentiation.	OR2A7 OR2A4	5.09e-05	3	144	2	27315375
Pubmed	NOX2-dependent ROS is required for HDAC5 nuclear efflux and contributes to HDAC4 nuclear efflux during intense repetitive activity of fast skeletal muscle fibers.	HDAC5 HDAC4	5.09e-05	3	144	2	22648949
Pubmed	G betagamma binds histone deacetylase 5 (HDAC5) and inhibits its transcriptional co-repression activity.	HDAC5 HDAC4	5.09e-05	3	144	2	16221676
Pubmed	Neddylation Regulates Class IIa and III Histone Deacetylases to Mediate Myoblast Differentiation.	HDAC5 HDAC4	5.09e-05	3	144	2	34502418
Pubmed	Histone deacetylase 5 is a phosphorylation substrate of protein kinase D in osteoclasts.	HDAC5 HDAC4	5.09e-05	3	144	2	35318161
Pubmed	Dephosphorylation at a conserved SP motif governs cAMP sensitivity and nuclear localization of class IIa histone deacetylases.	HDAC5 HDAC4	5.09e-05	3	144	2	23297420
Pubmed	A FAK/HDAC5 signaling axis controls osteocyte mechanotransduction.	HDAC5 HDAC4	5.09e-05	3	144	2	32612176
Pubmed	Divergent origins and concerted expansion of two segmental duplications on chromosome 16.	NPIPB3 NPIPB5	5.09e-05	3	144	2	11948212
Pubmed	Local phosphocycling mediated by LOK/SLK restricts ezrin function to the apical aspect of epithelial cells.	SLK STK10	5.09e-05	3	144	2	23209304
Pubmed	Stat3 inhibits PTPN13 expression in squamous cell lung carcinoma through recruitment of HDAC5.	HDAC5 PTPN13	5.09e-05	3	144	2	24191246
Pubmed	Investigating the Role of FoxP3 in Renal Cell Carcinoma Metastasis with BAP1 or SEDT2 Mutation.	SETD2 FOXP3	5.09e-05	3	144	2	37569676
Pubmed	Several dual specificity phosphatases coordinate to control the magnitude and duration of JNK activation in signaling response to oxidative stress.	ATF2 DUSP10	5.09e-05	3	144	2	17681939
Pubmed	Transcriptional regulation of a metastasis suppressor gene by Tip60 and beta-catenin complexes.	HDAC5 HDAC4 NCOR1	5.42e-05	18	144	3	15829968
Pubmed	A systems-wide screen identifies substrates of the SCFβTrCP ubiquitin ligase.	HIVEP2 PER1 REST PTPN13 FAM120A AKAP13 DYNC1H1	5.44e-05	232	144	7	25515538
Pubmed	Systematic identification of SH3 domain-mediated human protein-protein interactions by peptide array target screening.	DOCK3 AFF2 PRX FASTK NEK8 UHMK1 SMARCD1 LRBA	7.27e-05	329	144	8	17474147
Pubmed	LncRNAs-directed PTEN enzymatic switch governs epithelial-mesenchymal transition.	ZNF318 FAM13B PTPN13 AKAP13 CLNK CCDC93	7.47e-05	168	144	6	30631154
Pubmed	Menin and Menin-Associated Proteins Coregulate Cancer Energy Metabolism.	KIF13B SF3A1 INTS1 MED1 RFC5 NCOR1 YY1AP1 FOXK1	9.32e-05	341	144	8	32971831
Pubmed	Molecular mechanism of transcriptional repression of AhR repressor involving ANKRA2, HDAC4, and HDAC5.	HDAC5 HDAC4	1.02e-04	4	144	2	17949687
Pubmed	Ultrafine mapping of SNPs from mouse strains C57BL/6J, DBA/2J, and C57BLKS/J for loci contributing to diabetes and atherosclerosis susceptibility.	DOCK4 RRM2	1.02e-04	4	144	2	15793261
Pubmed	Restoration of the Mendelian transmission ratio by a deletion in the mouse chromosome 1 HSR.	CHRNG SAG	1.02e-04	4	144	2	9717434
Pubmed	JNK-ATF-2 inhibits thrombomodulin (TM) expression by recruiting histone deacetylase4 (HDAC4) and forming a transcriptional repression complex in the TM promoter.	HDAC4 ATF2	1.02e-04	4	144	2	20116378
Pubmed	KLF7 Alleviates Atherosclerotic Lesions and Inhibits Glucose Metabolic Reprogramming in Macrophages by Regulating HDAC4/miR-148b-3p/NCOR1.	HDAC4 NCOR1	1.02e-04	4	144	2	35439761
Pubmed	A zonal organization of odorant receptor gene expression in the olfactory epithelium.	OR2A7 OR2A4	1.02e-04	4	144	2	7683976
Pubmed	STAT3-mediated epigenetic silencing of FOXP3 in LADA T cells is regulated through HDAC5 and DNMT1.	HDAC5 FOXP3	1.02e-04	4	144	2	29223407
Pubmed	The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3.	HDAC4 NCOR1	1.02e-04	4	144	2	11509652
Pubmed	Profound defects in pupillary responses to light in TRPM-channel null mice: a role for TRPM channels in non-image-forming photoreception.	TRPM3 TRPM1	1.02e-04	4	144	2	22211741
Pubmed	Up-regulation of HO-1 promotes resistance of B-cell acute lymphocytic leukemia cells to HDAC4/5 inhibitor LMK-235 via the Smad7 pathway.	HDAC5 HDAC4	1.02e-04	4	144	2	29886060
Pubmed	SIK1 is a class II HDAC kinase that promotes survival of skeletal myocytes.	HDAC5 HDAC4	1.02e-04	4	144	2	17468767
Pubmed	Activation segment dimerization: a mechanism for kinase autophosphorylation of non-consensus sites.	SLK STK10	1.02e-04	4	144	2	18239682
Pubmed	SIKs control osteocyte responses to parathyroid hormone.	HDAC5 HDAC4	1.02e-04	4	144	2	27759007
Pubmed	mHDA1/HDAC5 histone deacetylase interacts with and represses MEF2A transcriptional activity.	HDAC5 HDAC4	1.02e-04	4	144	2	10748098
Pubmed	TEL contacts multiple co-repressors and specifically associates with histone deacetylase-3.	ETV6 NCOR1	1.02e-04	4	144	2	11439334
Pubmed	Cell autonomy of the mouse claw paw mutation.	LGI4 PRX	1.02e-04	4	144	2	15282162
Pubmed	Identification of SCAN domain zinc-finger gene ZNF449 as a novel factor of chondrogenesis.	ZNF449 SOX6	1.02e-04	4	144	2	25546433
Pubmed	Exercise-induced GLUT4 transcription via inactivation of HDAC4/5 in mouse skeletal muscle in an AMPKα2-dependent manner.	HDAC5 HDAC4	1.02e-04	4	144	2	28688716
Pubmed	The human gene CXorf17 encodes a member of a novel family of putative transmembrane proteins: cDNA cloning and characterization of CXorf17 and its mouse ortholog orf34.	FAM120B FAM120A	1.02e-04	4	144	2	14585507
Pubmed	FOXP3 up-regulates p21 expression by site-specific inhibition of histone deacetylase 2/histone deacetylase 4 association to the locus.	HDAC4 FOXP3	1.02e-04	4	144	2	19276356
Pubmed	PTHrP targets HDAC4 and HDAC5 to repress chondrocyte hypertrophy.	HDAC5 HDAC4	1.02e-04	4	144	2	30843886
Pubmed	CD98-induced CD147 signaling stabilizes the Foxp3 protein to maintain tissue homeostasis.	SLC7A5 FOXP3	1.02e-04	4	144	2	34759371
Pubmed	Class IIa histone deacetylases: conducting development and differentiation.	HDAC5 HDAC4	1.02e-04	4	144	2	19412888
Pubmed	The leukemia-associated fusion protein Tel-platelet-derived growth factor receptor β (Tel-PdgfRβ) inhibits transcriptional repression of PTPN13 gene by interferon consensus sequence binding protein (Icsbp).	ETV6 PTPN13	1.02e-04	4	144	2	22262849
Pubmed	Binding of microtubule-associated protein 1B to LIS1 affects the interaction between dynein and LIS1.	DNAH8 DYNC1H1	1.02e-04	4	144	2	15762842
Pubmed	A combination of SILAC and nucleotide acyl phosphate labelling reveals unexpected targets of the Rsk inhibitor BI-D1870.	SLK STK10	1.02e-04	4	144	2	27919044
Pubmed	HDAC4 and 5 repression of TBX5 is relieved by protein kinase D1.	HDAC5 HDAC4	1.02e-04	4	144	2	31784580
Pubmed	SRCAP complex promotes lung cancer progression by reprograming the oncogenic transcription of Hippo-YAP/TAZ signaling pathway.	SLK ATG2B ZNF318 MED1 NCOR1 SETD2 PTPN13 LRBA DYNC1H1 CSTF2T	1.03e-04	549	144	10	38280479
Pubmed	Genome-Wide CRISPR-Cas9 Screen Reveals Selective Vulnerability of ATRX-Mutant Cancers to WEE1 Inhibition.	ATP6V1B2 RRM2 TUBGCP6 SMARCD1	1.07e-04	59	144	4	31551363
Pubmed	Analysis of BCL6-interacting proteins by tandem mass spectrometry.	KIF13B HDAC5 HDAC4 NCOR1	1.30e-04	62	144	4	16147992
Pubmed	Gene network analysis in a pediatric cohort identifies novel lung function genes.	ETV6 TUBGCP6 FOXK1	1.32e-04	24	144	3	24023788
Pubmed	Comprehensive proteomic analysis of interphase and mitotic 14-3-3-binding proteins.	HDAC5 HDAC4 VIRMA NADK AKAP13 DYNC1H1	1.47e-04	190	144	6	15161933
Pubmed	Regulation of skeletal myogenesis by association of the MEF2 transcription factor with class II histone deacetylases.	HDAC5 HDAC4	1.69e-04	5	144	2	10983972
Pubmed	Functional interaction between class II histone deacetylases and ICP0 of herpes simplex virus type 1.	HDAC5 HDAC4	1.69e-04	5	144	2	15194749
Pubmed	Circadian clock and output genes are rhythmically expressed in extratesticular ducts and accessory organs of mice.	ATP6V1B2 PER1	1.69e-04	5	144	2	18945877
Pubmed	A novel corepressor, BCoR-L1, represses transcription through an interaction with CtBP.	HDAC5 HDAC4	1.69e-04	5	144	2	17379597
Pubmed	Regulation of MEF2 by histone deacetylase 4- and SIRT1 deacetylase-mediated lysine modifications.	HDAC5 HDAC4	1.69e-04	5	144	2	16166628
Pubmed	CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy.	HDAC5 HDAC4	1.69e-04	5	144	2	16767219
Pubmed	Transcriptional activation of hypoxia-inducible factor-1alpha by HDAC4 and HDAC5 involves differential recruitment of p300 and FIH-1.	HDAC5 HDAC4	1.69e-04	5	144	2	19071119
Pubmed	The POZ/BTB protein NAC1 interacts with two different histone deacetylases in neuronal-like cultures.	HDAC4 NCOR1	1.69e-04	5	144	2	16033423
Pubmed	Activation of the myocyte enhancer factor-2 transcription factor by calcium/calmodulin-dependent protein kinase-stimulated binding of 14-3-3 to histone deacetylase 5.	HDAC5 HDAC4	1.69e-04	5	144	2	11114197
Pubmed	Histone deacetylase 5 acquires calcium/calmodulin-dependent kinase II responsiveness by oligomerization with histone deacetylase 4.	HDAC5 HDAC4	1.69e-04	5	144	2	18332106
Pubmed	Altered interaction of HDAC5 with GATA-1 during MEL cell differentiation.	HDAC5 HDAC4	1.69e-04	5	144	2	14668799
Pubmed	Immediate effects of a single exercise bout on protein O-GlcNAcylation and chromatin regulation of cardiac hypertrophy.	HDAC5 HDAC4	1.69e-04	5	144	2	23624624
Pubmed	Assessment of the expression and role of the α1-nAChR subunit in efferent cholinergic function during the development of the mammalian cochlea.	MYO6 CHRNG	1.69e-04	5	144	2	27098031
Pubmed	HDAC4 integrates PTH and sympathetic signaling in osteoblasts.	HDAC5 HDAC4	1.69e-04	5	144	2	24934156
Pubmed	Myocyte enhancer factor 2 and class II histone deacetylases control a gender-specific pathway of cardioprotection mediated by the estrogen receptor.	HDAC5 HDAC4	1.69e-04	5	144	2	19893013
Interaction	TOP3B interactions	DOCK3 PDE2A HIVEP2 HDAC4 TRIO MYO6 CNOT10 INTS1 PER1 RRM2 IDUA ZZEF1 ARSG TYK2 STK10 NCOR1 CELSR1 TNRC18 FAM120A PSME4 MOGS ARVCF FASTK KLHL21 NEK8 NADK SLC7A5 AKAP13 WDFY3 LRBA SLC52A2 MBD5 DYNC1H1 FOXK1	2.00e-10	1470	138	34	int:TOP3B
Interaction	AHRR interactions	HDAC5 HDAC4 VIRMA	1.08e-05	7	138	3	int:AHRR
Interaction	NFATC1 interactions	HDAC5 HDAC4 OBSL1 RFC5 ATF2 SMARCD1 FOXK1 FOXP3	2.09e-05	168	138	8	int:NFATC1
Interaction	BAG2 interactions	KIF13B SLK HDAC5 HDAC4 SF3A1 OBSL1 ZNF318 RRM2 VIRMA EFTUD2 TYK2 TUBGCP6 NCOR1 FOXK1 CSTF2T	2.43e-05	622	138	15	int:BAG2
Interaction	LGALS3BP interactions	SOX6 HDAC5 OBSL1 ETV6 REST VIRMA TYK2 TUBGCP6 FAM120A MOGS	2.83e-05	286	138	10	int:LGALS3BP
Cytoband	16p12.2	NPIPB4 NPIPB3 NPIPB5 ERN2	5.66e-06	37	144	4	16p12.2
Cytoband	7p22.1	TNRC18 RNF216 FOXK1	4.43e-04	47	144	3	7p22.1
GeneFamily	Histone deacetylases, class IIA	HDAC5 HDAC4	1.66e-04	4	96	2	992
GeneFamily	WD repeat domain containing\|BEACH domain containing	WDFY3 LRBA	9.80e-04	9	96	2	1230
Coexpression	DACOSTA_UV_RESPONSE_VIA_ERCC3_DN	DOCK4 USP13 SLK HIVEP2 HDAC4 TRIO NPIPB3 MED1 ZZEF1 ATF2 GMPS STK10 SETD2 PTPN13 PSME4 AKAP13 ATP13A3 WDFY3 CCDC93	2.24e-07	856	143	19	M4500
Coexpression	MARTIN_INTERACT_WITH_HDAC	ETV6 REST ATF2 NCOR1 FOXP3	2.88e-06	41	143	5	M15154
Coexpression	GSE2585_AIRE_KO_VS_WT_CD80_HIGH_MTEC_UP	ZNF449 TRIO MYO6 ZNF318 IDUA FAM120A FASTK UHMK1	1.47e-05	200	143	8	M6266
ToppCell	nucseq\|World / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	DOCK4 NPIPB4 TRIO ETV6 NPIPB3 NPIPB5 AKAP13 ATP13A3 LRBA	1.41e-08	193	144	9	779276e775cb2492e8dd36436295a536084a6415
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	SOX6 MYO6 LRP1B CELSR1 PTPN13 MAST4 TRPM3 LRBA	2.27e-07	193	144	8	82e8a4c40299ffcdfd5a0da711bb9de6fb8a2eaa
ToppCell	facs-Pancreas-Exocrine-3m-Epithelial-pancreatic_B_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	KIF13B AFF2 TRIM43 ITGAD KY MAST4 TRPM3	1.61e-06	174	144	7	f1fe1f4216748a9562dd03bd48c70b23c7ff4d1d
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_principal_cell-Inner_Medullary_Collecting_Duct_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	SOX6 KIF13B MYO6 ETV6 LRP1B PTPN13 LRBA	2.99e-06	191	144	7	3e828cffa24ded19f591a7ed6c1fe88ad57fdcac
ToppCell	renal_cortex_nuclei\|World / Celltypes from Cells and Nuclei per compartment and clinical group	SOX6 TRIO MAST4 TRPM3 AKAP13 LRBA MBD5	3.10e-06	192	144	7	e8cc4d08fcfceeab75a02558817e4ccd7dbafe3a
ToppCell	facs-Pancreas-Exocrine-3m-Epithelial-nan\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ZNF449 AFF2 TRPM3 UHMK1 DSCR8 LRBA	1.14e-05	155	144	6	441fcb6d05364fc6f4973f0b973f1a80b573ce1f
ToppCell	E15.5-Mesenchymal-mesenchymal_fibroblast-tracheal_fibroblast\|E15.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	SOX6 PER1 IDUA MELTF PRELP CACNA1G	1.42e-05	161	144	6	9703b7e67d9fadb6129cad166bd01be915042e44
ToppCell	metastatic_Brain-T/NK_cells-Exhausted_Tfh\|metastatic_Brain / Location, Cell class and cell subclass	NPIPB4 NAA80 STK10 NCOR1 AKAP13 FOXP3	2.27e-05	175	144	6	b732c6a423c28856211002107d8c611dcfb6f265
ToppCell	PND14-Immune-Immune_Myeloid-Monocytic-Macrophage-AM-AM_prolif\|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	DOCK4 FAM78B RRM2 EFTUD2 MOGS ATP13A3	2.35e-05	176	144	6	450c25ec5eeb65425f904e0a25aaafdf5682ef9c
ToppCell	Smart-seq2-tissue-resident_(Smart-seq2)-myeloid-myeloid_granulocytic-mast_cell\|tissue-resident_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	KIF13B TRIO GNPTAB MELTF AKAP13 DUSP10	3.10e-05	185	144	6	3fafb1d36c5f98a29d20a5ce5192c83d6f603514
ToppCell	CV-Moderate-7\|CV / Virus stimulation, Condition and Cluster	GNPTAB FANCL NPIPB5 ITGAD SHPRH LRBA	3.20e-05	186	144	6	8571956890fc9894d766ba294a28e376b4aba428
ToppCell	PBMC-Severe-Myeloid-Neutrophil-Neutrophil-Neu_4\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	PRTN3 ATG2B ETV6 RRM2 RFC5 AGL	3.60e-05	190	144	6	3f0c7d130f66faea778fe567604edf1b4cdf85b3
ToppCell	COPD-Lymphoid-T_Regulatory\|Lymphoid / Disease state, Lineage and Cell class	MAST4 PGAP1 ATP13A3 CLNK DNAH8 FOXP3	3.71e-05	191	144	6	3ae18bc4e3dff49b5d5958da8ebc3f747274b69c
ToppCell	368C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_0.5\|CD8+_Cytotoxic_T-cell / Donor, Lineage, Cell class and subclass (all cells)	ZZEF1 FASTK CEP83 SLC52A2 DYNC1H1 FOXK1	3.82e-05	192	144	6	efbd52b3d2b6d3fb9ed6bc3f36aca9f4f1fcbc49
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive\|renal_cortex_nuclei / Celltypes from Cells and Nuclei per compartment and clinical group	HIVEP2 TRIO ETV6 STK10 AKAP13 ATP13A3	3.82e-05	192	144	6	8b86db2ebe0199fee0e9800566a619a24bfdeed5
ToppCell	PBMC-Severe-Myeloid-Neutrophil-Neutrophil-Neu_4\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	PRTN3 ATG2B ETV6 RRM2 RFC5 AGL	3.82e-05	192	144	6	c09dcc73ff9c3855a0f3d7bfa0d5c99c09a117f2
ToppCell	TCGA-Prostate-Primary_Tumor-Prostate_Adenocarcinoma-Acinar_Adenocarcinoma-6\|TCGA-Prostate / Sample_Type by Project: Shred V9	ZBTB41 MED1 FAM120A UHMK1 WDFY3 DYNC1H1	3.93e-05	193	144	6	abd71b2cf667ef2b1c4d88acd0c1dd19a12ff659
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Epithelial\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	SOX6 MYO6 PTPN13 MAST4 TRPM3 LRBA	3.93e-05	193	144	6	3866667dd221612589ae50f5c52f73a183a49ce6
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Epithelial-Collecting_tubule_epithelial_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	SOX6 KIF13B MYO6 LRP1B PTPN13 LRBA	4.05e-05	194	144	6	04bfc555743f7d8821439d05ae442d15e9886c59
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_principal_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	SOX6 KIF13B MYO6 LRP1B PTPN13 LRBA	4.05e-05	194	144	6	69bff17df4a760ccf081cf52ff04af02c14f448d
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Epithelial\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	SOX6 MYO6 LRP1B PTPN13 MAST4 LRBA	4.16e-05	195	144	6	6477e6e7be5bd8eb99119a12ae16334ccddecd43
ToppCell	Parenchymal-NucSeq\|Parenchymal / Cell types per location group and 10X technology with lineage, and cell group designations	DOCK4 TRIO PTPN13 WDFY3 LRBA MBD5	4.53e-05	198	144	6	1996373bdccc55aac347d349bd22f6aad6d0c668
ToppCell	mild-unassigned\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	USP13 AFF2 TUBGCP6 PTPN13 ARVCF FOXK1	4.79e-05	200	144	6	ca0a08bf162c954f037a56aa0cbb8b5d7c6ffec0
ToppCell	facs-Brain_Non-Myeloid-Striatum-24m-Macroglial-astrocyte\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	REST TRPM3 AGL PGAP1 CCDC40	5.00e-05	123	144	5	a45d6907c041ad3f3218cd46dccfc25d4bd961cb
Drug	Acebutolol hydrochloride [34381-68-5]; Up 200; 10.8uM; PC3; HG-U133A	SLK STK10 PSME4 ARVCF FASTK KLHL21 MED25 RNF216 AKAP13 CCDC40	3.94e-07	195	141	10	1911_UP
Drug	Pentylenetetrazole [54-95-5]; Down 200; 29uM; PC3; HT_HG-U133A	HIVEP2 HDAC4 RNF19B CREB3L1 TSKU MAST4 NADK RNF216 CCDC93	3.96e-06	197	141	9	2092_DN
Drug	Tomatidine [77-59-8]; Up 200; 9.6uM; HL60; HG-U133A	PRPSAP2 DOCK4 HDAC5 INTS1 ITIH2 NCOR1 FASTK NADK AKAP13	4.13e-06	198	141	9	1754_UP
Drug	Meptazinol hydrochloride [59263-76-2]; Down 200; 14.8uM; MCF7; HT_HG-U133A	RNF19B REST ERN2 TGFB3 PTPN13 NADK SMARCD1 WDFY3 CCDC93	4.30e-06	199	141	9	7326_DN
Drug	cellopentaose	HDAC4 TSKU AGL UHMK1 LRBA	8.49e-06	45	141	5	CID000440949
Drug	2-deoxy-D-glucose; Up 200; 10000uM; MCF7; HG-U133A	TRIO ZZEF1 ATF2 SETD2 ARVCF DUSP10 WDFY3 SLC33A1	2.14e-05	186	141	8	344_UP
Drug	2-propylpentanoic acid; Down 200; 1000uM; PC3; HG-U133A	HIVEP2 TRIO IDUA ERN2 TYK2 KLHL21 NADK SMARCD1	2.69e-05	192	141	8	458_DN
Drug	Glycocholic acid [475-31-0]; Down 200; 8.6uM; MCF7; HT_HG-U133A	KIF13B ATF2 TSKU NCOR1 MAST4 SMARCD1 AKAP13 CSTF2T	2.90e-05	194	141	8	5316_DN
Drug	Kawain [500-64-1]; Up 200; 17.4uM; MCF7; HT_HG-U133A	CA9 CYP17A1 LRP1B ITIH2 PRX MED25 CSTF2T CCDC40	2.90e-05	194	141	8	2299_UP
Drug	Oxybutynin chloride [1508-65-2]; Down 200; 10.2uM; MCF7; HT_HG-U133A	RNF19B PER1 ZNF318 ATF2 MAST4 ARVCF MED25 CSTF2T	2.90e-05	194	141	8	3168_DN
Drug	Tiabendazole [148-79-8]; Down 200; 19.8uM; MCF7; HT_HG-U133A	HIVEP2 HDAC5 CYP17A1 IDUA ERN2 ARVCF WDFY3 CSTF2T	3.00e-05	195	141	8	4402_DN
Drug	Apomorphine hydrochloride hemihydrate [41372-20-7]; Up 200; 6.4uM; PC3; HG-U133A	CA9 KIF13B REST TSKU STK10 NCOR1 AKAP13 DYNC1H1	3.12e-05	196	141	8	1923_UP
Drug	Trimethadione [127-48-0]; Down 200; 28uM; MCF7; HT_HG-U133A	KIF13B AFF2 PER1 ETV6 REST ERN2 ARVCF CSTF2T	3.12e-05	196	141	8	4165_DN
Drug	Indomethacin [53-86-1]; Up 200; 11.2uM; PC3; HT_HG-U133A	CA9 NAA80 BRINP1 ZZEF1 ITIH2 MELTF SMARCD1 CACNA1G	3.23e-05	197	141	8	5049_UP
Drug	Ajmaline [4360-12-7]; Down 200; 12.2uM; MCF7; HT_HG-U133A	GNPTAB ERN2 ZZEF1 TGFB3 ARVCF NADK WDFY3 CSTF2T	3.23e-05	197	141	8	2899_DN
Drug	Ketorolac tromethamine [74103-07-4]; Down 200; 10.6uM; PC3; HT_HG-U133A	HDAC5 CYP17A1 RNF19B OBSL1 ZNF318 ATF2 ATP13A3 CSTF2T	3.23e-05	197	141	8	7286_DN
Drug	Betonicine [515-25-3]; Down 200; 25.2uM; MCF7; HT_HG-U133A	AFF2 TRIO RNF19B IDUA ZZEF1 SETD2 PGAP1 WDFY3	3.23e-05	197	141	8	4767_DN
Drug	Bergenin monohydrate [477-90-7]; Up 200; 11.6uM; PC3; HT_HG-U133A	PDE2A PRTN3 ERN2 CHRNG NCOR1 MAST4 PGAP1 DUSP10	3.35e-05	198	141	8	5870_UP
Drug	Dimaprit dihydrochloride [23256-33-9]; Up 200; 17uM; MCF7; HT_HG-U133A	HIVEP2 GNPTAB ZNF318 ITIH2 CHRNG PRELP MED25 CCDC40	3.35e-05	198	141	8	6520_UP
Drug	rosiglitazone; Down 200; 10uM; HL60; HT_HG-U133A	MYO6 RNF19B BRINP1 REST ZZEF1 PGAP1 MED25 CACNA1G	3.47e-05	199	141	8	2693_DN
Drug	Denatonium benzoate [3734-33-6]; Up 200; 9uM; PC3; HT_HG-U133A	CA9 INTS1 CHRNG MAST4 TRPM3 MED25 TRPM1 FOXP3	3.47e-05	199	141	8	5061_UP
Drug	Nizatidine [76963-41-2]; Down 200; 12uM; PC3; HT_HG-U133A	HDAC5 TSKU SETD2 PTPN13 MAST4 PGAP1 RNF216 WDFY3	3.47e-05	199	141	8	6305_DN
Drug	Iobenguane sulfate; Down 200; 10.8uM; MCF7; HT_HG-U133A	HIVEP2 GNPTAB PER1 ETV6 ERN2 ZZEF1 SEMA4G CCDC93	3.47e-05	199	141	8	2878_DN
Drug	alpha-estradiol; Up 200; 0.01uM; MCF7; HT_HG-U133A	CA9 ETV6 ZNF318 IDUA ERN2 MAST4 ARVCF CCDC93	3.60e-05	200	141	8	6970_UP
Drug	Lymecycline [992-21-2]; Down 200; 6.6uM; PC3; HT_HG-U133A	HDAC4 TRIO CYP17A1 RNF19B ATG2B PSME4 AGL PGAP1	3.60e-05	200	141	8	7291_DN
Drug	AC1LCMT1	CREB3L1 KY NCOR1	6.35e-05	13	141	3	CID000633349
Drug	p-nitrophenyl-alpha-D-glucopyranoside	CACNA1B TSKU MOGS TRPM3 AGL LRBA	8.60e-05	116	141	6	CID000065115
Drug	wortmannin; Up 200; 1uM; MCF7; HT_HG-U133A_EA	KIF13B HDAC5 ATG2B FAM13B DUSP10 WDFY3 CCDC93	1.12e-04	175	141	7	869_UP
Drug	adaptol	CREB3L1 TSKU	1.14e-04	3	141	2	CID000025381
Drug	Sp 1 (pharmaceutical)	PDE2A HDAC5 HDAC4 SF3A1 MED1 ITGAD LRP1B ATF2 TGFB3 NCOR1 SETD2 PRELP	1.60e-04	548	141	12	CID000099040
Drug	OPC-18790	PDE2A PER1 SLC33A1	1.77e-04	18	141	3	CID000060790
Drug	cox-2 inhibitor I; Up 200; 10uM; MCF7; HG-U133A	MYO6 OR5I1 IDUA PTPN13 ARVCF NADK DUSP10	1.86e-04	190	141	7	612_UP
Drug	Fenbufen [36330-85-5]; Down 200; 15.8uM; PC3; HT_HG-U133A	TRIO REST MED1 RFC5 SETD2 PSME4 AKAP13	1.92e-04	191	141	7	4279_DN
Drug	Econazole nitrate [24169-02-6]; Up 200; 9uM; MCF7; HT_HG-U133A	INTS1 ETV6 NAA80 ZZEF1 NADK SMARCD1 FOXP3	1.92e-04	191	141	7	6008_UP
Drug	Rapamycin; Down 200; 0.1uM; MCF7; HT_HG-U133A	TRIO RNF19B MED1 ERN2 FASTK RNF216 WDFY3	2.05e-04	193	141	7	5239_DN
Drug	triethyltin	PRTN3 ETV6 AKAP13	2.09e-04	19	141	3	CID005359541
Drug	Dimenhydrinate [523-87-5]; Down 200; 8.6uM; MCF7; HT_HG-U133A	NAA80 ZNF318 NCOR1 SETD2 ARVCF NADK SMARCD1	2.11e-04	194	141	7	5450_DN
Drug	Cimetidine [51481-61-9]; Down 200; 15.8uM; PC3; HG-U133A	TRIO MYO6 SF3A1 OBSL1 MAST4 FASTK NADK	2.11e-04	194	141	7	1884_DN
Drug	phentolamine; Up 200; 11.5uM; MCF7; HT_HG-U133A_EA	ZNF318 ATF2 STK10 OXA1L FASTK KLHL21 AKAP13	2.11e-04	194	141	7	1138_UP
Drug	Chlorhexidine [55-56-1]; Down 200; 8uM; PC3; HG-U133A	TRIO MYO6 MED1 RFC5 FASTK NADK SLC52A2	2.18e-04	195	141	7	1942_DN
Drug	Palmatine chloride [3486-67-7]; Up 200; 10.4uM; MCF7; HT_HG-U133A	KIF13B HDAC5 RNF19B ZNF318 SAG ARVCF WDFY3	2.18e-04	195	141	7	2795_UP
Drug	Trimeprazine tartrate [4330-99-8]; Up 200; 5.4uM; HL60; HT_HG-U133A	MYO6 BRINP1 ZZEF1 TSKU PRELP CACNA1G TRPM1	2.18e-04	195	141	7	2736_UP
Drug	Imipramine hydrochloride [113-52-0]; Up 200; 12.6uM; MCF7; HT_HG-U133A	AFF2 TRIO CYP17A1 ETV6 IDUA ZZEF1 CHRNG	2.18e-04	195	141	7	5440_UP
Drug	Ethisterone [434-03-7]; Down 200; 12.8uM; MCF7; HT_HG-U133A	TRIO REST ERN2 PSME4 KLHL21 SMARCD1 ATP13A3	2.18e-04	195	141	7	3864_DN
Drug	Proglumide [6620-60-6]; Down 200; 12uM; MCF7; HT_HG-U133A	CYP17A1 REST IDUA ZZEF1 SEMA4G SAG PSME4	2.18e-04	195	141	7	3972_DN
Drug	Moxalactam disodium salt [64953-12-4]; Up 200; 7uM; HL60; HT_HG-U133A	AFF2 TRIO BRINP1 MELTF MED25 TRPM1 CCDC40	2.18e-04	195	141	7	3028_UP
Drug	Allantoin [97-59-6]; Down 200; 25.2uM; MCF7; HT_HG-U133A	SF3A1 ZZEF1 MAST4 KLHL21 NADK SMARCD1 CCDC93	2.25e-04	196	141	7	1678_DN
Drug	Apomorphine hydrochloride hemihydrate [41372-20-7]; Up 200; 6.4uM; MCF7; HT_HG-U133A	KIF13B HDAC4 CREB3L1 SEMA4G NCOR1 CACNA1G CSTF2T	2.25e-04	196	141	7	1505_UP
Drug	Moricizine hydrochloride [31883-05-3]; Down 200; 8.6uM; PC3; HT_HG-U133A	CYP17A1 RNF19B TGFB3 PSME4 RNF216 AKAP13 CSTF2T	2.25e-04	196	141	7	7297_DN
Drug	Pyridoxine hydrochloride [58-56-0]; Down 200; 19.4uM; MCF7; HT_HG-U133A	HIVEP2 ERN2 NCOR1 FASTK NADK SMARCD1 CCDC93	2.25e-04	196	141	7	2751_DN
Drug	monastrol; Down 200; 100uM; MCF7; HG-U133A	PRPSAP2 TRIO ERN2 TYK2 NCOR1 FAM120A SLC52A2	2.25e-04	196	141	7	627_DN
Drug	Buflomedil hydrochloride [35543-24-9]; Down 200; 11.6uM; HL60; HT_HG-U133A	ATF2 PSME4 NADK RNF216 DUSP10 ATP13A3 CCDC93	2.25e-04	196	141	7	1338_DN
Drug	Gliclazide [21187-98-4]; Up 200; 12.4uM; HL60; HG-U133A	GNPTAB NAA80 ERN2 ARVCF FASTK KLHL21 RNF216	2.25e-04	196	141	7	1720_UP
Drug	SCN-Bz-DTPA	PRTN3 TSKU	2.27e-04	4	141	2	CID000124173
Drug	Bupropion hydrochloride [31677-93-7]; Up 200; 14.4uM; HL60; HG-U133A	CA9 RNF19B MED1 TSKU NCOR1 NADK CSTF2T	2.32e-04	197	141	7	1564_UP
Drug	estradiol, USP; Down 200; 0.1uM; HL60; HT_HG-U133A	TRIO MYO6 OBSL1 ERN2 ZZEF1 MED25 CACNA1G	2.32e-04	197	141	7	2668_DN
Drug	Dihydrostreptomycin sulfate [5490-27-7]; Up 200; 2.8uM; PC3; HT_HG-U133A	ERN2 SEMA4G TSKU NADK SMARCD1 RNF216 WDFY3	2.32e-04	197	141	7	2074_UP
Drug	Cefuroxime sodium salt [56238-63-2]; Up 200; 9uM; MCF7; HT_HG-U133A	HDAC5 RNF19B REST MED1 MAST4 PLEKHG6 ARVCF	2.32e-04	197	141	7	6261_UP
Drug	estradiol, USP; Down 200; 0.01uM; MCF7; HT_HG-U133A	KIF13B HDAC5 NAA80 REST ERN2 SEMA4G NADK	2.32e-04	197	141	7	5238_DN
Drug	aspirin, USP; Down 200; 100uM; MCF7; HT_HG-U133A	RNF19B PER1 ZNF318 ATF2 SETD2 MAST4 CSTF2T	2.32e-04	197	141	7	5201_DN
Drug	Prazosin hydrochloride [19237-84-4]; Up 200; 9.6uM; MCF7; HT_HG-U133A	RNF19B ZNF318 PRX CHRNG ARVCF NADK SMARCD1	2.32e-04	197	141	7	6475_UP
Drug	SC-58125; Up 200; 10uM; HL60; HG-U133A	KIF13B AFF2 BRINP1 MED1 ERN2 ARVCF KLHL21	2.32e-04	197	141	7	542_UP
Drug	Sulfadiazine [68-35-9]; Down 200; 16uM; PC3; HT_HG-U133A	HIVEP2 HDAC5 SEMA4G TGFB3 PTPN13 MOGS AKAP13	2.32e-04	197	141	7	1810_DN
Drug	Cefotaxime sodium salt [64485-93-4]; Down 200; 8.4uM; MCF7; HT_HG-U133A	SF3A1 RNF19B ERN2 NCOR1 SETD2 MAST4 CSTF2T	2.32e-04	197	141	7	7186_DN
Drug	Carbinoxamine maleate salt [3505-38-2]; Down 200; 9.8uM; PC3; HT_HG-U133A	SLK TGFB3 PSME4 PMPCA KLHL21 NADK AKAP13	2.32e-04	197	141	7	7138_DN
Drug	monastrol; Up 200; 100uM; MCF7; HG-U133A	CA9 OBSL1 IDUA ERN2 ARVCF NADK DUSP10	2.32e-04	197	141	7	610_UP
Drug	2-propylpentanoic acid; Down 200; 50uM; MCF7; HT_HG-U133A	TRIO RNF19B ZNF318 SEMA4G MAST4 NADK CCDC93	2.39e-04	198	141	7	5219_DN
Drug	Noscapine [128-62-1]; Up 200; 9.6uM; HL60; HG-U133A	HDAC5 SAG PSME4 ARVCF KLHL21 RNF216 CCDC93	2.39e-04	198	141	7	1753_UP
Drug	N6,2-O-dibutyryladenosine 3,5-cyclic monophosphate sodium salt; Down 200; 2uM; MCF7; HT_HG-U133A_EA	RNF19B REST MED1 STK10 MAST4 MED25 RNF216	2.39e-04	198	141	7	842_DN
Drug	PHA-00851261E [724719-49-7]; Up 200; 1uM; PC3; HT_HG-U133A	REST MED1 RFC5 ERN2 MELTF ARVCF MED25	2.39e-04	198	141	7	4333_UP
Drug	Dubinidine [22964-77-8]; Down 200; 14.6uM; MCF7; HT_HG-U133A	HIVEP2 ZNF318 PTPN13 FASTK RNF216 AKAP13 SLC33A1	2.39e-04	198	141	7	6250_DN
Drug	Cefotetan [69712-56-7]; Down 200; 7uM; MCF7; HT_HG-U133A	PER1 ZNF318 ITIH2 KLHL21 PGAP1 NADK WDFY3	2.39e-04	198	141	7	4116_DN
Drug	Pepstatin A [26305-03-3]; Up 200; 5.8uM; MCF7; HT_HG-U133A	HIVEP2 CYP17A1 NAA80 ERN2 MED25 CACNA1G DUSP10	2.39e-04	198	141	7	4790_UP
Drug	Guanethidine sulfate [60-02-6]; Down 200; 13.4uM; PC3; HT_HG-U133A	HDAC5 RNF19B ERN2 TGFB3 TSKU PGAP1 ATP13A3	2.39e-04	198	141	7	5731_DN
Drug	tetraethylenepentamine pentahydrochloride; Up 200; 100uM; PC3; HG-U133A	ZZEF1 CREB3L1 TSKU MAST4 FASTK ATP13A3 CSTF2T	2.39e-04	198	141	7	457_UP
Drug	Tolfenamic acid [13710-19-5]; Up 200; 15.2uM; PC3; HT_HG-U133A	PDE2A REST IDUA ERN2 CREB3L1 MED25 CCDC40	2.39e-04	198	141	7	6354_UP
Drug	Amodiaquin dihydrochloride dihydrate [6398-98-7]; Down 200; 8.6uM; MCF7; HT_HG-U133A	INTS1 ERN2 ATF2 NCOR1 SETD2 MAST4 FASTK	2.39e-04	198	141	7	6224_DN
Drug	Pepstatin A [26305-03-3]; Down 200; 5.8uM; MCF7; HT_HG-U133A	TRIO RNF19B ERN2 MAST4 PLEKHG6 ARVCF AKAP13	2.39e-04	198	141	7	3264_DN
Drug	Diflunisal [22494-42-4]; Up 200; 16uM; MCF7; HT_HG-U133A	REST ITIH2 CHRNG STK10 MED25 NADK SMARCD1	2.39e-04	198	141	7	1490_UP
Drug	methylparaben	PDE2A CREB3L1 KY	2.45e-04	20	141	3	CID000007456
Drug	Natamycin [7681-93-8]; Down 200; 6uM; MCF7; HT_HG-U133A	MOGS ARVCF FASTK RNF216 WDFY3 SLC52A2 CSTF2T	2.47e-04	199	141	7	3548_DN
Drug	Folinic acid calcium salt [6035-45-6]; Down 200; 7.8uM; MCF7; HT_HG-U133A	HDAC5 TRIO RNF19B PER1 NAA80 BRINP1 ZZEF1	2.47e-04	199	141	7	4725_DN
Drug	Vincamine [1617-90-9]; Up 200; 11.2uM; PC3; HT_HG-U133A	DOCK3 PDE2A NAA80 SAG ARVCF PRELP CACNA1G	2.47e-04	199	141	7	3784_UP
Drug	Leucomisine [17946-87-1]; Up 200; 16.2uM; PC3; HT_HG-U133A	KIF13B CYP17A1 ERN2 CREB3L1 MAST4 MED25 DUSP10	2.47e-04	199	141	7	7125_UP
Drug	Hydrastinine hydrochloride [4884-68-8]; Up 200; 16.4uM; HL60; HG-U133A	AFF2 NAA80 ZNF318 SAG NADK AKAP13 ATP13A3	2.47e-04	199	141	7	1436_UP
Drug	Levodopa [59-92-7]; Up 200; 20.2uM; PC3; HG-U133A	AFF2 ZNRF4 STK10 ARVCF FASTK MED25 NADK	2.47e-04	199	141	7	1892_UP
Drug	Ethosuximide [77-67-8]; Up 200; 28.4uM; PC3; HT_HG-U133A	KIF13B MYO6 ETV6 REST MAST4 WDFY3 CCDC40	2.47e-04	199	141	7	7308_UP
Drug	Piroxicam [36322-90-4]; Down 200; 12uM; MCF7; HT_HG-U133A	KIF13B RNF19B REST ERN2 PLEKHG6 ARVCF DUSP10	2.47e-04	199	141	7	2252_DN
Drug	Norcyclobenzaprine [303-50-4]; Down 200; 15.4uM; MCF7; HT_HG-U133A	FASTK NADK SMARCD1 RNF216 AKAP13 WDFY3 CSTF2T	2.47e-04	199	141	7	2830_DN
Drug	Drofenine hydrochloride [548-66-3]; Down 200; 11.4uM; PC3; HT_HG-U133A	HIVEP2 HDAC5 CELSR1 PSME4 CEP83 AKAP13 CSTF2T	2.55e-04	200	141	7	7129_DN
Drug	Omeprazole [73590-58-6]; Up 200; 11.6uM; PC3; HT_HG-U133A	CELSR1 ARVCF TRPM3 PRELP MED25 CACNA1G DUSP10	2.55e-04	200	141	7	6606_UP
Drug	Ketotifen fumarate [34580-14-8]; Down 200; 9.4uM; PC3; HT_HG-U133A	TRIO CYP17A1 ZNF318 MAST4 MED25 AKAP13 CSTF2T	2.55e-04	200	141	7	5842_DN
Drug	triethylamine	RRM2 CREB3L1 LRBA DYNC1H1	2.60e-04	50	141	4	CID000008471
Disease	Intellectual Disability	CACNA1B HIVEP2 HDAC4 TRIO LGI4 SETD2 TRPM3 SMARCD1 CACNA1G DYNC1H1	3.95e-05	447	134	10	C3714756
Disease	Familial primary pulmonary hypertension	HDAC5 HDAC4 ATP13A3	5.94e-05	17	134	3	C0340543
Disease	Arthrogryposis	LGI4 CHRNG DYNC1H1	1.15e-04	21	134	3	C0003886
Disease	mood instability measurement	SOX6 HIVEP2 BRINP1 LRP1B FOXK1	3.03e-04	128	134	5	EFO_0008475
Disease	Myeloid Leukemia, Chronic	CA9 PRTN3 PER1	3.07e-04	29	134	3	C0023473
Disease	Global developmental delay	CACNA1B INTS1 LGI4 TRPM3 SMARCD1	3.62e-04	133	134	5	C0557874
Disease	Pulmonary Hypertension, Primary, 1, With Hereditary Hemorrhagic Telangiectasia	HDAC5 HDAC4	4.24e-04	7	134	2	C3714844
Disease	Pulmonary Hypertension, Primary, 1	HDAC5 HDAC4	4.24e-04	7	134	2	C4552070
Disease	PULMONARY HYPERTENSION, PRIMARY, DEXFENFLURAMINE-ASSOCIATED	HDAC5 HDAC4	4.24e-04	7	134	2	C1969342
Disease	Pulmonary Hypertension, Primary, Fenfluramine-Associated	HDAC5 HDAC4	4.24e-04	7	134	2	C1969343
Disease	MASA syndrome (implicated_via_orthology)	TRPM3 TRPM1	4.24e-04	7	134	2	DOID:0060246 (implicated_via_orthology)
Disease	NEPHRONOPHTHISIS 2	NEK8 CEP83	5.63e-04	8	134	2	C1865872
Disease	colon cancer (is_implicated_in)	LRP1B PTPN13 SLC7A5	5.86e-04	36	134	3	DOID:219 (is_implicated_in)
Disease	autism spectrum disorder (implicated_via_orthology)	BRINP1 ARVCF SLC7A5 WDFY3 LRBA	6.65e-04	152	134	5	DOID:0060041 (implicated_via_orthology)
Disease	epilepsy (implicated_via_orthology)	CACNA1B TRIO LRP1B SLC13A5 DYNC1H1	9.10e-04	163	134	5	DOID:1826 (implicated_via_orthology)
Disease	Paranoia	TYK2 DNAH8	1.10e-03	11	134	2	C1456784
Disease	Night blindness, congenital stationary, type 1	SAG TRPM1	1.31e-03	12	134	2	C3501847
Disease	Night Blindness, Congenital Stationary, Type 1A	SAG TRPM1	1.31e-03	12	134	2	C3495587
Disease	NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 2B (disorder)	SAG TRPM1	1.31e-03	12	134	2	C1864877
Disease	outer ear morphology trait	HIVEP2 LRBA	1.31e-03	12	134	2	EFO_0007664
Disease	NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1B	SAG TRPM1	1.31e-03	12	134	2	C1850362
Disease	X-Linked Csnb	SAG TRPM1	1.31e-03	12	134	2	C3711543
Disease	NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 2A	SAG TRPM1	1.31e-03	12	134	2	C1848172
Disease	lung adenocarcinoma (is_implicated_in)	LRP1B SETD2 PTPN13	1.45e-03	49	134	3	DOID:3910 (is_implicated_in)
Disease	Cone-rod synaptic disorder, congenital nonprogressive	SAG TRPM1	1.55e-03	13	134	2	C4041558
Disease	gallbladder cancer (is_implicated_in)	CYP17A1 LRP1B	1.55e-03	13	134	2	DOID:3121 (is_implicated_in)
Disease	malignant pleural mesothelioma (is_marker_for)	SETD2 SLC7A5	1.80e-03	14	134	2	DOID:7474 (is_marker_for)
Disease	Drug habituation	SLK MYO6 ETV6 DNAH8	1.90e-03	115	134	4	C0013170
Disease	Drug abuse	SLK MYO6 ETV6 DNAH8	1.90e-03	115	134	4	C0013146
Disease	Prescription Drug Abuse	SLK MYO6 ETV6 DNAH8	1.90e-03	115	134	4	C4316881
Disease	Substance-Related Disorders	SLK MYO6 ETV6 DNAH8	1.90e-03	115	134	4	C0236969
Disease	Drug Use Disorders	SLK MYO6 ETV6 DNAH8	1.90e-03	115	134	4	C0013222
Disease	Drug Dependence	SLK MYO6 ETV6 DNAH8	1.90e-03	115	134	4	C1510472
Disease	Substance Dependence	SLK MYO6 ETV6 DNAH8	1.90e-03	115	134	4	C0038580
Disease	Substance Use Disorders	SLK MYO6 ETV6 DNAH8	1.90e-03	115	134	4	C0038586
Disease	Organic Mental Disorders, Substance-Induced	SLK MYO6 ETV6 DNAH8	1.90e-03	115	134	4	C0029231
Disease	Substance abuse problem	SLK MYO6 ETV6 DNAH8	1.97e-03	116	134	4	C0740858
Disease	Cocaine-Related Disorders	HDAC5 HDAC4 TYK2 DNAH8	2.03e-03	117	134	4	C0236736
Disease	Generalized hypotonia	TRPM3 SMARCD1	2.07e-03	15	134	2	C1858120
Disease	colorectal cancer (is_implicated_in)	LRP1B SETD2 PTPN13 FOXP3	2.29e-03	121	134	4	DOID:9256 (is_implicated_in)
Disease	5-oxoproline measurement	SLC52A2 DNAH8	2.36e-03	16	134	2	EFO_0010988
Disease	colorectal mucinous adenocarcinoma	ETV6 TRPM1	2.36e-03	16	134	2	EFO_0009361
Disease	Idiopathic pulmonary arterial hypertension	HDAC5 HDAC4	2.36e-03	16	134	2	C3203102
Disease	hepatocellular carcinoma (is_marker_for)	CA9 HDAC4 LRP1B EFTUD2 SLC7A5 FOXP3	2.59e-03	301	134	6	DOID:684 (is_marker_for)
Disease	hemoglobin A1 measurement	SOX6 ITGAD ARSG SETD2 MELTF ARVCF KLHL21 AKAP13	2.65e-03	520	134	8	EFO_0007629
Disease	esophageal carcinoma, gastric carcinoma	ATG2B TRPM1	2.66e-03	17	134	2	EFO_0000178, EFO_0002916
Disease	Night blindness, congenital stationary	SAG TRPM1	2.66e-03	17	134	2	C0339535
Disease	alpha-L-iduronidase measurement	GNPTAB IDUA	2.66e-03	17	134	2	EFO_0020139
Disease	autosomal dominant intellectual developmental disorder (is_implicated_in)	TRIO SETD2	2.66e-03	17	134	2	DOID:0060307 (is_implicated_in)
Disease	Cocaine Abuse	HDAC5 HDAC4 TYK2 DNAH8	2.73e-03	127	134	4	C0009171
Disease	serum dimethylarginine measurement	LRP1B TSKU PTPN13	2.98e-03	63	134	3	EFO_0005418
Disease	seborrheic dermatitis	TNRC18 MAST4	3.69e-03	20	134	2	EFO_1000764
Disease	Cocaine Dependence	HDAC5 HDAC4 TYK2 DNAH8	3.77e-03	139	134	4	C0600427
Disease	Nystagmus	AFF2 MAST4	4.06e-03	21	134	2	HP_0000639
Disease	vital capacity	SOX6 HIVEP2 PER1 MED1 ZZEF1 KY NCOR1 MELTF CEP83 NADK DUSP10 LRBA FOXK1	4.19e-03	1236	134	13	EFO_0004312

Protein segments in the cluster

Peptide	Gene	Start	Entry
LVPPVSSLRPNQMLD	LINC00311	41	Q8N616
PKEHLALLAVPMVPL	SLC33A1	341	O00400
RLPIPHQAPGEMTQL	CREB3L1	166	Q96BA8
MLPLLSPLLRHTAEP	ANTXRL	606	A6NF34
PEVLAMLRHPVDPVK	ARVCF	361	O00192
VRHPVPLMPEFQRSI	BRINP1	91	O60477
PLIIRIQVLNPPSVM	BPIFB4	476	P59827
ALHNRIMPTVVRPPK	ATP13A3	581	Q9H7F0
VVFVLVPLRDLPPMH	APOBEC4	291	Q8WW27
LPQLLRMHVRPLAPA	CHRNG	351	P07510
MPPPSVVILNSTLIH	AFF2	136	P51816
IPVMQTEILSPLRDH	AFF2	781	P51816
RILSRMEPIPPNALV	FAM78B	221	Q5VT40
PLTNMLEVVSHPHPV	AKAP13	751	Q12802
HMQIERAPSVPPFLR	BCL2L12	26	Q9HB09
ALAHMHVPLPVTQLP	ARSG	246	Q96EG1
PLLLHLPNGQTMPVA	ATF2	216	P15336
MVLHYLQTLPEPILP	TENT2	336	Q6PIY7
VATEVPFRLMHPQPE	SAG	351	P10523
HNEFRSLILVPNMPP	CEP83	626	Q9Y592
SLRLPHRPIINTPMV	CELSR1	2361	Q9NYQ6
PPDPNTIVHIPVMLT	CACNA1B	1071	Q00975
PRIVLKINPPAMHSI	ATG2B	846	Q96BY7
LLVPVHPQRLPRMQE	CA9	31	Q16790
PQLHPQQMIISRHLP	NPIPB3	766	Q92617
PPRPHDVTLVAQLSM	LARGE2	426	Q8N3Y3
GLMLLIRIDPHLQTP	OR5I1	46	Q13606
LEVEALPLQMCRHPP	OBSL1	1801	O75147
LPLQMCRHPPREKTV	OBSL1	1806	O75147
VMAAPPARPDHTRLL	PCDHGA4	31	Q9Y5G9
TPLHVPVPRALRMEE	ETV6	31	P41212
SPIMHPLILNPRHSV	ETV6	271	P41212
RPEELTPHVMVLLAQ	FASTK	231	Q14296
VGAQIVLAHMELPPP	REST	676	Q13127
MAPPQRHPQRSEQVL	PCDHGA6	1	Q9Y5G7
LPPLTPDLLHQLMVE	KLHL33	181	A6NCF5
RHPPVLRMVLEALQA	H1-8	51	Q8IZA3
PVELLNPARVNHMPS	HDAC4	16	P56524
SPLLQHMVLLEQPPA	HDAC4	411	P56524
HMVLLEQPPAQAPLV	HDAC4	416	P56524
ILRSDIPHQPMGIIA	LRP1B	2441	Q9NZR2
PVLQVHPLESPAMIS	FOXP3	116	Q9BZS1
VPMLVLDPALPANIT	GNPTAB	136	Q3T906
VVHAMVILLTLGPPR	INTS1	1166	Q8N201
QVLESTPPPHVMRVE	ITIH2	686	P19823
MLLSPHPTLEAAPVV	NAA80	106	Q93015
LTVEVHPRDAMPQLL	KY	91	Q8NBH2
PPVLHTTMLRVHPTL	ERN2	366	Q76MJ5
PEPVIPGSLHIHLMQ	FAM13B	106	Q9NYF5
NEPSRVMPSQPLHIV	DUSP10	241	Q9Y6W6
IHPNVPAIMITPICP	NADK	336	O95544
APVLLFLHPEDRPLM	PER1	391	O15534
VAPLAPDTQVLVMPL	PDE2A	136	O00408
LISVMKRELPRHPPT	DNAH8	2916	Q96JB1
LEPAQRPPLSHIMAQ	NEK8	241	Q86SG6
RPPLSHIMAQPLCIR	NEK8	246	Q86SG6
SILSMIHPQLLTPVP	SLC7A5	361	Q01650
LLIEPHPPRGSAMQV	LRBA	2481	P50851
PQLHPQQMIISRHLP	NPIPB5	681	A8MRT5
DPRHMVLVRGLVLPV	MED25	216	Q71SY5
ESMSEPPIAHLLRPV	TUBGCP6	1436	Q96RT7
VQPIPCLLSMPTRNH	FAM120A	526	Q9NZB2
TVPRMLVNLLHPAKP	OR2A7	76	Q96R45
PLITLPITMHFPTAV	OXA1L	301	Q15070
MAHRPPSPALASVLL	PRTN3	1	P24158
PQLHPQQMIISRHLP	NPIPB4	686	C9JG80
NPPTLLLPVAHMLEV	MOGS	511	Q13724
TVPRMLVNLLHPAKP	OR2A4	76	O95047
PIPLHIRPEAVNMSL	ITGAD	76	Q13349
PQLHPQQMIISRHLP	NPIPB11	696	E5RHQ5
QRMRGPHIIQLDTPL	PLEKHG6	771	Q3KR16
VSVLPRMKCPHQLEP	CCDC93	91	Q567U6
MPVILTPLHFDRDPL	GMPS	611	P49915
RVRLHGVPPDMLQLL	KLHL21	76	Q9UJP4
PQPEVRNIMIPIFHD	DOCK3	1106	Q8IZD9
IPQPDLRNVMIPIFH	DOCK4	1076	Q8N1I0
LPPLIIHTAATPMSL	CACNA1G	1036	O43497
LRLRPVAPMLIPHKA	CYP17A1	361	P05093
SQLVVLDPDHPLMVR	CCDC40	276	Q4G0X9
KIHIPEPDLRSMVSP	FOXK1	226	P85037
LHLPVQEILMSQPPE	DSCR8	46	Q96T75
PPHVQLLRKPVLTAM	IDUA	376	P35475
KMHSPPTIVRHIVRP	MAST4	1416	O15021
IHLNRTPLSPPSVML	MBD5	266	Q9P267
EIPEISLPIHPMITN	DYNC1H1	201	Q14204
EPPVAPHLMEQLARL	KLHDC9	231	Q8NEP7
AIHPSLEIPMLIPKE	PRPSAP2	236	O60256
PRALSILMLPHNIPS	COQ9	201	O75208
HLARRPVKDIPPLMQ	CSTF2T	241	Q9H0L4
IPTEMLPQHRALPLD	HDAC5	341	Q9UQL6
QMEPLHAVPPAAITL	SLC13A5	436	Q86YT5
NPLRHPDLVRPLQMT	FAM120B	656	Q96EK7
VPHPQPSIQRMVRLS	MED1	756	Q15648
LPRIPMLPHLLPDIT	PTPN13	1871	Q12923
PQLHPQQMIISRHLP	NPIPB13	686	A6NJU9
SPLAHQPVPRIMVQS	KIF13B	1481	Q9NQT8
NLRPDPEPLLTEMIH	PMPCA	196	Q10713
IPILTMPNDDITHPI	ATP6V1B2	351	P21281
ESVLLHMPQPVNPEL	TRIM43	256	Q96BQ3
NPHDIRLLLADPPLM	RNF19B	171	Q6ZMZ0
IEPPHHELNPMRVLL	SLK	231	Q9H2G2
QIPPHAVMVRPDTNI	MELTF	621	P08582
EIPQRLHALLMPPEP	SMARCD1	356	Q96GM5
LHALLMPPEPIIINH	SMARCD1	361	Q96GM5
MPPEPIIINHVISVD	SMARCD1	366	Q96GM5
NSIPDHVVPEMLRCP	TDRD9	516	Q8NDG6
LLRETSLMPHIPGLP	TDRD9	1211	Q8NDG6
INIEVDPRHPTMLPE	FANCL	236	Q9NW38
PPALVAPRAFAHITM	LGI4	496	Q8N135
PLTPELMVPRLEHVV	RFC5	176	P40937
DLPQLQHRAAVIPPM	NCOR1	926	O75376
MAAPTPARPVLTHLL	SLC52A2	1	Q9HAB3
IMRLTPLSDPALAPH	PRSS47P	321	A8MTI9
MELLIARHPGIPPTL	SHPRH	1076	Q149N8
PAPNPRRVMSQEHLL	SHISA7	376	A6NL88
LLITQATPHVAPVMP	PGAP1	196	Q75T13
ATPHVAPVMPLDRFI	PGAP1	201	Q75T13
NILRKMPPRVPTAIH	PRELP	231	P51888
ERIPMLVTPAPQQHE	RNF216	41	Q9NWF9
IHAPRINVVPMPPSA	SF3A1	621	Q15459
PLMIPIFPHDQRTLA	SOX6	266	P35712
PLSQRHTFPEVQRMP	CLNK	186	Q7Z7G1
SMIHPKEVPPEAILL	CNOT10	671	Q9H9A5
TRPPAPMQILILTLD	SHANK2-AS3	66	Q9BTD1
LPHFAELMERATVPP	TNRC18	866	O15417
IRDIETLPPNMHEPI	WDFY3	2576	Q8IZQ1
VKLHPLMARPVVPTR	SEMA4G	401	Q9NTN9
MLSLRVPLAPITDPQ	RRM2	1	P31350
MTFHERPVLPPPLII	TRPM3	1161	Q9HCF6
EMAVPDVHLPEVQLP	PRX	646	Q9BXM0
GQRPQALPPETIHLM	PSTK	191	Q8IV42
PANIVHPVRPEQMLD	ZBTB41	866	Q5SVQ8
AQIEPPHHELNPMRV	STK10	231	O94804
PEHLMPRASRVPVAA	ZNRF4	6	Q8WWF5
EMPPLQPKHLREAVR	nan	166	A6NLC8
LQNLALMRPELVIPP	PSME4	421	Q14997
PVALPHTPITVLMAA	SETD2	211	Q9BYW2
QLIMTFHDRPVLPPP	TRPM1	1096	Q7Z4N2
FHDRPVLPPPMIILS	TRPM1	1101	Q7Z4N2
KMVLRIPHPIQPATV	YY1AP1	491	Q9H869
QMLSEERVVPHLPLA	ZZEF1	2811	O43149
ESVLLHMPQPVNPEL	TRIM43B	256	A6NCK2
LEPQPAPHLAREFMI	EFTUD2	921	Q15029
LHSQQQVRAPIPMVP	HIVEP2	2216	P31629
IMPVPIPLDTAHLDL	TSKU	51	Q8WUA8
PLPLPMQTTQVIEPH	VIRMA	1121	Q69YN4
PEPHRIMPITKQATR	ZNF318	816	Q5VUA4
IPFAPHIEDLVMLPT	UHMK1	306	Q8TAS1
PHLILMMIPPHRLDN	TGFB3	276	P10600
ELLVPHMPTIRVPRS	USP13	26	Q92995
HIPPTMHLESPALQV	ZNF449	136	Q6P9G9
AVPLPPPMAIQQHSL	TRIO	1866	O75962
PPNHILEIPRDASLM	TYK2	86	P29597
QPCLRPLMPAIAHAL	AGL	606	P35573
MPPRILLNTDVAPFI	LEG1	266	Q6P5S2
IARQMELHPDKPPIL	MYO6	1211	Q9UM54
FMPIAPTSEPLHLIV	MYBPC2	731	Q14324